Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Ah-See ML, Lowe ES, Lukashchuk N, Carter D, Penson RT. Scambia G, et al. Among authors: lowe es. J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933. Online ahead of print. J Clin Oncol. 2024. PMID: 39668137
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Francis KE, Simon S, Gebski V, Joly F, Ledermann JA, Penson RT, Oza AM, Korach J, Lainez N, Cecere SC, Tasca G, Gropp-Meier M, Fujiwara K, Lowe ES, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Among authors: lowe es. Gynecol Oncol. 2024 Nov 12;192:50-55. doi: 10.1016/j.ygyno.2024.11.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39536691 Free article.
Structural and functional studies of the EGF20-27 region reveal new features of the human Notch receptor important for optimal activation.
Bo Z, Rowntree T, Johnson S, Nurmahdi H, Suckling RJ, Hill J, Korona B, Weisshuhn PC, Sheppard D, Meng Y, Liang S, Lowe ED, Lea SM, Redfield C, Handford PA. Bo Z, et al. Among authors: lowe ed. Structure. 2024 Dec 5;32(12):2325-2336.e5. doi: 10.1016/j.str.2024.10.012. Epub 2024 Nov 1. Structure. 2024. PMID: 39488203 Free article.
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years.
Goldenberg NA, Schulman S, Kittelson JM, Abshire TC, Casella JF, Dale R, Halperin JL, Hanson J, Kessler CM, Manco-Johnson MJ, McDevitt L, Sidonio RF, Spyropoulos AC, Steg PG, Bonaca MP; Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) Trial Investigators and the Antithrombotic Trials Leadership and Steering (ATLAS) Group. Goldenberg NA, et al. J Thromb Haemost. 2024 Oct 24:S1538-7836(24)00631-7. doi: 10.1016/j.jtha.2024.09.038. Online ahead of print. J Thromb Haemost. 2024. PMID: 39461724
Author Correction: The mycobacterial glycoside hydrolase LamH enables capsular arabinomannan release and stimulates growth.
Franklin A, Salgueiro VC, Layton AJ, Sullivan R, Mize T, Vázquez-Iniesta L, Benedict ST, Gurcha SS, Anso I, Besra GS, Banzhaf M, Lovering AL, Williams SJ, Guerin ME, Scott NE, Prados-Rosales R, Lowe EC, Moynihan PJ. Franklin A, et al. Among authors: lowe ec. Nat Commun. 2024 Aug 21;15(1):7155. doi: 10.1038/s41467-024-51724-9. Nat Commun. 2024. PMID: 39169049 Free PMC article. No abstract available.
461 results